Niranjan Bose

@AlzData, @niranjanbose reminds the #ADPD2026 community that the #AI $1M prize will be announced later today, and you can tune in from around the world! @adpdnet Tune into the livestream on LinkedIn at 1:20 PM CET | 8:20 AM ET. lnkd.in/e2URTRG8

Go for the kill @SoundersFC. We know you can do it! #soundersmatchday

Supercharging Alzheimer’s Research: Gates Ventures Backs a Million-Dolla... youtu.be/vbwJWZeqMaE?si… via @YouTube

Not today boys!!! This is Sounders Stadium!!! @SoundersFC Leagues Cup 2025!!!

Here they come 💚

What a fantastic day for the beautiful game! @SoundersFC vs Inter Miami featuring the GOAT. Let’s go Sounders and let’s go Messi!

New USD 1 million prize competition aims to revolutionize Alzheimer's research by leveraging agentic AI systems backed by Bill Gates ethealthworld.com/s/ygxjk8g via @ETHealthWorld

Bill Gates and @AlzData coalition funds $1mn AI Alzheimer’s prize ft.com/content/b93286… via @ft

The AI Alzheimer’s prize is the latest effort to deploy the promising technology to find cures for humanity’s toughest illnesses. on.ft.com/4lTFEWl

I'm proud to share that applications are now open for the $1 million Alzheimer’s Insights AI Prize for ADRD research – a global competition to find new, AI-driven solutions to speed up our fight against Alzheimer's disease. @AlzData Apply here: alzheimersdata.org/alzinsights-pr…

With 40,000 blood and CSF samples, the GNPC’s neurodegeneration proteomics dataset is the largest disease-specific effort yet. #alzheimersdisease @_neuroproteome ow.ly/s0Ks50WhQbs

🎊We are delighted to have signed an MoU with Gates Ventures to mark the beginning of a long-term association centered on scientific #research and capacity-building in the realm of healthy and pathological #brain #aging. 🔬🩺This alliance combines CBR’s clinical and scientific expertise with Gates Ventures’ longstanding commitment to overcoming R&D challenges in #Alzheimers and related dementias. 🧠It aims to leverage recent advances in the use of fluid #biomarkers to predict the onset and monitor the progression of #dementia and other #neurodegenerative conditions. ⚙️It will reinforce efforts to develop scalable, inexpensive, and minimally invasive approaches which, together with sophisticated digital tools, are likely to positively impact the field of aging brain research. 🤝This innovative collaboration will be further fortified by the active involvement of the @UKDRI, which brings rich expertise in aging brain research and will play a vital role in facilitating knowledge exchange. A key initiative under this multi-institutional endeavour will be the establishment of a✨Biomarker Centre of Excellence✨at CBR to systematically evaluate existing blood biomarkers and potentially discover new ones relevant to the Indian population. Efforts will also focus on developing scalable tests that move from conventional venous blood draws to simpler, at-home 'finger-prick' methods. 🖥️The partnership will strive to create a forward-looking ecosystem in India that consolidates multidisciplinary expertise, state-of-the-art computational infrastructure, robust #data science methodologies, and access to large, diverse, and longitudinal #health datasets. Such an integrated approach is expected to foster innovation and improvement in healthcare outcomes pertaining to brain aging. 📈This cooperation will be enabled via @AlzData and the Global Research and Imaging Platform (GRIP), which are co-funded and supported by Gates Ventures. “We are excited about this unique partnership with CBR that reflects Gates Ventures’ resolve to help overcome R&D bottlenecks in neurodegeneration, particularly Alzheimer’s disease and related dementias. It represents a significant step towards harnessing the power of data and innovation to understand the complexities of brain aging”, says Dr. @niranjanbose, Managing Director, Health & Life Sciences, Gates Ventures. Prof. @kvshari, Director, CBR, says: “At CBR, we aspire to pursue global science with a local context. Joining hands with Gates Ventures is a remarkable milestone that exemplifies this ethos. Together, we look forward to being able to translate cutting-edge research into scalable, culturally relevant solutions that address the challenges of brain disorders affecting the elderly in India.” 🌐This MoU builds on CBR’s growing network of international collaborations, including the recent partnership with the @UKDRI and @HDR_UK. These collective efforts underscore a shared vision to strengthen global research in brain aging and associated diseases. @kris_sg @iiscbangalore

The USC Clinical Trial Recruitment Lab calls for more inclusive, equitable access to Alzheimer’s clinical trials in a new @journal_ad paper—featuring insights from leaders across the field, including ADDF Board Members @niranjanbose and @PhylFerrell. bit.ly/43FGqjK

Let’s break this record #Seattle @SoundersFC We are coming for you San Jose! @GWR welcome to Seattle!

ADDF’s Diagnostics Accelerator (DxA) published a paper in Alzheimer’s & Dementia providing a landscape review of blood & ocular biomarkers presenting the opportunity to identify at-risk individuals who may otherwise go undiagnosed. @niranjanbose bit.ly/3DCUZu4

#LAFC you come you play you lose. Rinse and repeat! #Soundersmatchday

Let’s go Sounders FC! #soundersmatchday

Q&A: BCG on the US healthcare system and the use of AI shar.es/agemqJ via @MobiHealthNews good to see a consulting firm provide their perspective.... are there solutions to propose as well? There are some clues in the interview but not called out explicitly.

@AlzData The integration of the @imi_epnd Hub and the AD Workbench provides more opportunities for researchers to collaborate, share, access and analyse data to further our shared goal of accelerating discoveries in neurodegenerative disease research @niranjanbose epnd.org/news/epnd-laun…

@TheADDF's Diagnostics Accelerator (DxA) invests $10M in @AlamarBio to Advance Precision Medicine in #Alzheimers Disease biospace.com/press-releases…